Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04022382 · ClinicalTrials.gov registry record · NA

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

A NA study of Dry Eye, sponsored by John C Meyer, MD.

Completed
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT04022382 is a NA study of Dry Eye that has completed, run by John C Meyer, MD. The registered enrollment target is 17 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04022382, a NA study of Dry Eye, has completed, sponsored by John C Meyer, MD.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with 0.1ml Restylane Defyne and the other eye injected with 0.2ml Restylane Defyne. Participants will be evaluated over four visits.

Conditions Studied

Interventions

  • DEVICE Restylane Defyne

Study Locations (1)

Kentucky

  • The Eye Care Institute - Louisville

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2019-07-18
Est. Completion 2019-08-26
Phase NA

Sponsor

John C Meyer, MD

2 total trials

What the Registry Record Tells You About NCT04022382

The ClinicalTrials.gov registry entry for NCT04022382 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (82% lower). The listed sponsor is John C Meyer, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Restylane Defyne is the first listed.

NCT04022382 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT04022382 about?

NCT04022382 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion". A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with 0.1ml Restylane Defyne and the other eye injected with 0.2ml Restylane Defyne. Participants will be evaluated over four visits.

What is the current status of trial NCT04022382?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-07-18. Estimated completion is 2019-08-26.

What conditions does trial NCT04022382 study?

This clinical trial studies the following conditions: Dry Eye.

What interventions are being tested in trial NCT04022382?

The interventions under investigation include: Restylane Defyne (DEVICE).

Who is sponsoring clinical trial NCT04022382?

This trial is sponsored by John C Meyer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04022382 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.